Predictive value of N-terminal pro-B-type natriuretic peptide (NT-pro BNP) combined with D-dimer for no-reflow phenomenon in patients with acute coronary syndrome after emergency of percutaneous coronary intervention

Diao, Yujing; Yin, Meifeng; Zhang, Baoguo; Sun, Bin

doi:10.1080/21655979.2021.1988361

Cited by 8 publications

(3 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In ACS patients with STsegment elevation myocardial infarction (STEMI), the increase in NT-proBNP levels is attributable to acute myocardial infarction, which induces the release of NT-proBNP from the Short Communication ventricles due to elevated stress on the left ventricular wall [15][16][17][18]. NT-proBNP levels can also be used to assess silent myocardial ischemia [19,20]. NT-proBNP is also associated with the regulation of various physiological functions that control energy metabolism, myocardial ischemia, and the development of organ damage, including left ventricular hypertrophy and peripheral artery disease.…”

Section: Discussionmentioning

confidence: 99%

Association between NT-proBNP level and the number of stents with major advanced cardiovascular events (MACE) in patients with multivessel coronary artery disease treated with percutaneous coronary intervention: A prospective cohort study

Subkhan,

Heriansyah,

Munirwan

et al. 2024

Narra J

View full text Add to dashboard Cite

Complex revascularization strategies, particularly complete revascularization, are controversial in coronary artery disease (CAD), and data supporting routine revascularization in stable CAD is lacking. The importance of percutaneous coronary intervention (PCI) in CAD and N-terminal pro-brain natriuretic peptide (NT-proBNP), which has been studied as a predictor of major advanced cardiovascular events (MACE) in CAD patients, still requires further research. The aim of this study was to determine the association between NT-proBNP levels and the number of stents with MACE incidence in CAD cases. A prospective cohort study was conducted in both types of CAD (acute coronary syndrome (ACS) and chronic coronary syndrome (CCS)). The NT-proBNP levels were measured pre- and post-PCI using fluorescence immunoassay, while MACE was assessed three months post-PCI. The Student t-test was used to compare the levels of NT-proBNP between pre- and post-PCI and between those who had MACE and did not; both in patients treated with single or multiple stenting groups. A total of 32 CAD patients were recruited, consisting of 20 ACS cases and 12 CCS cases. NT-proBNP levels post-PCI increased significantly in both ACS and CCS patients compared to pre-PCI either among those treated with single and multiple stentings. MACE occurred in 4 (12.5%) out of a total of 32 patients, all of which occurred in ACS patients treated with multiple stentings. Those who had MACE had higher post-PCI NT-proBNP levels compared to those who did not have MACE (23,703.50 vs 11,600.17 pg/mL, p=0.013). This study highlights the association between elevated NT-proBNP levels and multiple stenting with the presence of MACE in CAD patients, particularly in ACS cases.

show abstract

Section: Discussionmentioning

confidence: 99%

Association between NT-proBNP level and the number of stents with major advanced cardiovascular events (MACE) in patients with multivessel coronary artery disease treated with percutaneous coronary intervention: A prospective cohort study

Subkhan,

Heriansyah,

Munirwan

et al. 2024

Narra J

View full text Add to dashboard Cite

show abstract

“…This study also found that NT-pro-BNP levels were higher in the no-reflow group than in the reflow group. The findings in this study indicate that preoperative levels of NT-pro-BNP in combination with D-dimer can also be used as predictive biomarkers for the incidence of no-reflow after PCI [ 28 ].…”

Section: Discussionmentioning

confidence: 99%

The Effects of Percutaneous Coronary Intervention on Biomarkers and Quality of Life in Patients With Chronic Total Coronary Artery Obstruction

et al. 2023

View full text Add to dashboard Cite

Background: Chronic total occlusion (CTO) is an angiographic picture of total occlusion without blood flow which is estimated to have lasted at least 3 months. This study attempted to provide an overview of the levels of matrix metalloproteinase-9 (MMP-9), soluble suppression tumorigenicity 2 (sST2), and N-terminal pro-B-type natriuretic peptide (NT-pro-BNP) as remodeling, inflammatory, and atherosclerotic markers, as well as changes in the angina severity in patients with CTO who underwent percutaneous coronary intervention (PCI) compared to those without PCI.Methods: This study is a preliminary report with quasi-experimental design study with a pre-test and post-test approach to compare PCI's effect in CTO patients towards changes in MMP-9, sST2, NT-pro-BNP levels, and changes in the angina severity. Twenty subjects underwent PCI and 20 subjects with optimal medical therapy, who were then assessed at baseline and 8 weeks after intervention. Results:The results of this preliminary report showed that decreased MMP-9 (pre-test: 12.07 ± 1.27 ng/mL vs. post-test: 9.91 ± 5.19 ng/ mL, P = 0.049), sST2 (pre-test: 37.65 ± 20.00 ng/mL vs. post-test: 29.74 ± 15.17 ng/mL, P = 0.026) and NT-pro-BNP (pre-test: 0.63 ± 0.23 ng/mL vs. post-test: 0.24 ± 0.10 ng/mL, P < 0.001) levels were found after 8 weeks of PCI compared to those without such intervention. The levels of NT-pro-BNP were lower in the PCI group (0.24 ± 0.10 ng/mL) than in the non-PCI group (0.56 ± 0.23 ng/mL; P < 0.001). Moreover, there was an improvement of angina severity in PCI group than without PCI (P < 0.039). Conclusions:Although this preliminary report found a significant decrease in MMP-9, NT-pro-BNP, and sST2 levels in CTO patients who had undergone PCI compared to those without PCI, as well as improved angina severity in these patients, this study still has limitations. The number of samples was so small that similar studies with larger sample sizes or multicenter investigations are required to deliver more trustworthy and useful results. Nevertheless, we encourage this study as a preliminary baseline for further studies in the future.

show abstract

“…2 The neurohormone N terminal pro-B-type natriuretic peptide (NT-proBNP), which is elevated in acute myocardial infarction and angina pectoris, is synthesized and released by ventricular muscles. 3 The two basic sources of BNP and NT-proBNP release are wall stress and myocyte stretch. Among its various activities are sympathetic nerve activation, natriuresis, vasodilation, and inhibition of the renin-angiotensin-aldosterone system.…”

Section: Introductionmentioning

confidence: 99%

Frequency of multi-vessel disease and its association with N Terminal-Pro Brain Natriuretic Peptide Levels among patients with First ST-Elevation Myocardial Infarction.

Sheikh,

Sarfaraz,

Sarfaraz

et al. 2024

Nepalese Heart J.

View full text Add to dashboard Cite

Background and Aims: To determine the frequency of multi-vessel disease among patients with First ST-Elevation Myocardial Infarction and to identify the cutoff value of N Terminal-Pro Brain Natriuretic Peptide (NT-proBNP) for diagnosis of multi-vessel disease. Methodology: A descriptive cross-sectional study was conducted in the Department of Cardiology at a tertiary care hospital from September 2021 to February 2022. The study included 150 patients who presented to the emergency room with first ST-elevation myocardial infarction and preserved ejection fraction. NT-proBNP levels were tested within 12 hours of hospital admission. The severity of coronary artery disease was assessed by the number of vessels affected labeled, the luminal diameter narrowing and the syntax score. Results: The mean age of participants was 60.60±11.1 years. 76% were men, 53.3% of the participants had hypertension, 44% had type 2 diabetes, and 14% were smokers. The mean BMI of the patients was 27.86±3.86. The mean ejection fraction of the patients was 50±4.5.Single-vessel disease was present in 47 (31%) and 103 (69%) had multi-vessel disease. The mean NT-proBNP level in single-vessel disease was 561.34 pg/mL, and in multi-vessel disease, it was 1640.65 pg/mL. Raised levels of NT-proBNP were significantly associated with the severity of coronary artery disease. (P-value <0.05). The optimal cut-off value of NTpro-BNP for ruling out multiple vessel disease was 947.50 pg/mL at 81% of sensitivity.Conclusion: Pro-BNP is a valuable biomarker in assessing the severity of coronary artery disease in STEMI patients. Its levels have been shown to correlate with the degree of CAD severity including multi-vessel involvement.

show abstract

Predictive value of N-terminal pro-B-type natriuretic peptide (NT-pro BNP) combined with D-dimer for no-reflow phenomenon in patients with acute coronary syndrome after emergency of percutaneous coronary intervention

Cited by 8 publications

References 34 publications

Association between NT-proBNP level and the number of stents with major advanced cardiovascular events (MACE) in patients with multivessel coronary artery disease treated with percutaneous coronary intervention: A prospective cohort study

Association between NT-proBNP level and the number of stents with major advanced cardiovascular events (MACE) in patients with multivessel coronary artery disease treated with percutaneous coronary intervention: A prospective cohort study

The Effects of Percutaneous Coronary Intervention on Biomarkers and Quality of Life in Patients With Chronic Total Coronary Artery Obstruction

Frequency of multi-vessel disease and its association with N Terminal-Pro Brain Natriuretic Peptide Levels among patients with First ST-Elevation Myocardial Infarction.

Contact Info

Product

Resources

About